Anti-CD33 CAR-TF tag mRNA-LNP
CD33 or Siglec-3 (sialic acid-binding Ig-like lectin 3) is a sialoadhesin molecule encoded by the CD33 gene, a member of the immunoglobulin supergene family. CD33 is a transmembrane receptor expressed on myeloid cells. It is considered an excellent bone marrow marker and is often used in the diagnosis of acute myeloid leukemia (AML). CD33 may be aberrantly expressed in some cases of plasma cell myeloma, but not on red blood cells, platelets, B cells, T cells, or NK cells. In normal cells, CD33 is involved in cell signaling, cell adhesion and cell growth. Cancer cells that produce too much CD33 may grow faster. Knowing whether a cancer is CD33 positive may help with treatment planning. Cancers that may be CD33 positive include acute myeloid leukemia and certain types of lymphoma. Approximately 10-20% of B or T lymphocytic leukemia/lymphomas may aberrantly express CD33. This product is designed as a tool for the delivery and expression of TF-tagged anti-CD33 CAR mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-CD33 CAR-TF mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The anti-CD33 CAR-TF in this product is approximately 56 kD and consists of anti-CD33 scFv (single-chain variable fragment) linked to a second-generation CAR (chimeric antigen receptor) containing the CD8 hinge and transmembrane domain and 4-1BB and CD3ζ signaling domains. The TF tag consists of 15 amino acids and is added at its C-terminus. The full-length amino acid sequence of this anti-CD33 CAR-TF mRNA-LNP product is available upon request.